EVENT: use of an evidence-based shared decision support tool on antipsychotics for hospitalised patients with schizophrenia

EVENT: use of an evidence-based shared decision support tool on antipsychotics for hospitalised patients with schizophrenia - EVENT

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

DRKS

Registry ID

DRKS00027316

Enrollment

248

Registered

2022-01-26

Start date

2022-01-31

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F20-F29

Interventions

Group 1: The decision-making process between patients and physicians regarding the selection of antipsychotics is digitally supported by the SDST Group 2: treatment-as-usual

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inpatients with a schizophrenia spectrum disorder, present on the ward at the time of the examination who are able to give their informed consent

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Shared-Decision-Making Questionnaire (SDM-Q-9), (patient version)	—

Secondary

Measure	Time frame
Physicians’ perceived involvement in decision-making (SDM-Q-9; physician version), treatment satisfaction, attitudes regarding treatment and adherence (ZUF-8, MARS, VAS), satisfaction regarding medication (MSQ, DAI), symptom severity/symptom improvement (PANSS-6), clinical global impression (CGP-I), global functioning (SOFAS), quality of life (EUROHIS-QOL), side-effects (UKU-SERS, VAS), and health-related data for example length of inpatient stay	—

Measure

Time frame

Physicians’ perceived involvement in decision-making (SDM-Q-9; physician version), treatment satisfaction, attitudes regarding treatment and adherence (ZUF-8, MARS, VAS), satisfaction regarding medication (MSQ, DAI), symptom severity/symptom improvement (PANSS-6), clinical global impression (CGP-I), global functioning (SOFAS), quality of life (EUROHIS-QOL), side-effects (UKU-SERS, VAS), and health-related data for example length of inpatient stay

—

Countries

Germany

Contacts

Public ContactJohannes Hamann

Klinikum rechts der Isar der TU München

johannes.hamann@tum.de089 41404223

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 12, 2026